The PDE4 inhibitor tanimilast shows distinct immunomodulatory properties associated with a type 2 endotype and CD141 upregulation.

J Transl Med · 2022 · PMC9092691 · PMID 35538539

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

In COPD patients, tanimilast exerted an add-on effect to inhaled corticosteroids with upregulation of the expression of TSP1, VEGF-A and AREG in sputum cells of the lung, while IDO1 modulation did not reach statistical significance (Table 2 ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.